Novaccess Global (Novaccess Global) Float Percentage Of Total Shares Outstanding : 33.14% (As of Jun. 19, 2024)

View and export this data going back to . Start your Free Trial

What is Novaccess Global Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Novaccess Global's float shares is 20.43 Mil. Novaccess Global's total shares outstanding is 61.63 Mil. Novaccess Global's float percentage of total shares outstanding is 33.14%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Novaccess Global's Insider Ownership is 1.45%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Novaccess Global's Institutional Ownership is 0.00%.

Novaccess Global Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Novaccess Global's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	20.43	/	61.63
	=	33.14%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novaccess Global (Novaccess Global) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novaccess Global Inc (OTCPK:XSNX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

8485 E,Washington Street, No. 127, Chagrin Falls, OH, USA, 44023

Website

https://www.novaccessglobal.com

Novaccess Global Inc is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States. The company's team of experts is working to strengthen the capability of the human body's defense against cancer.

Executives

Jason Michael Anderson	director	8584 E. WASHINGTON STREET, NO. 127, CHAGRIN FALLS OH 44023
John Cassarini	director	880 WINTER STREET, BUILDING 4, WALTHAM MA 02451
Neil J Laird	officer: Chief Financial Officer
Larry Michael Yukich	officer: Chief Financial Officer	8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Dwain Morris-irvin	officer: Chief Executive Officer	8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Innovest Global, Inc.	10 percent owner	8834 MAYFIELD ROAD, CHESTERLAND OH 44026
Daniel G. Martin	director, 10 percent owner, officer: Chief Executive Officer	8834 MAYFIELD RD, CHESTERLAND OH 44026
Michael A Russak	director
Osmund Mark Fundingsland	director	1237 LAS PALMAS DR, SANTA BARBARA CA 93110
Thomas A Anderson	director	2116 PASEO PRIMERO, SANTA FE NM 87501
Jeff J Huitt	officer: CFO	10651 WEST 34TH PLACE, WHEAT RIDGE CO 80033
Joseph Grimes	officer: COO	6 CLEOME, LADERA RANCH CA 92694
Tom M Djokovich	director, 10 percent owner, officer: President	23332 VISTA CARILLO, LAGUNA NIGUEL CA 92677
Brian Altounian	director, officer: Secretary	626 N. DOHENY DRIVE, WEST HOLLYWOOD CA 90069
Thomas Djokovich	director, officer: President	1601 CLOVERFIELD BLVD, 2ND FL. S. TOWER, SANTA MONICA CA 90404